ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme In Prostate Cancer Models
Halozyme Therapeutics,
Inc. (Nasdaq: HALO), a biopharmaceutical company developing and
commercializing products targeting the extracellular matrix,
announced the presentation of positive pre-clinical animal efficacy data
for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for
Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey,
CA. The study showed that treatment of hormone resistant human prostate
cancer in tumor bearing mouse models with intravenous PEGPH20 in
combination with the chemotherapeutic drugs, docetaxel (Taxotere(R)) or
liposomal doxorubicin (Doxil(R)) resulted in a substantial increase in
anti-tumor activity. The docetaxel combination treatment demonstrated
significantly enhanced survival compared to treatment with the
chemotherapeutic agent alone. The effects of PEGPH20 were selective to
prostate tumors producing hyaluronan (HA), consistent with the selective
reduction of tumor interstitial fluid pressure (IFP). Treatment with
PEGPH20 was well tolerated in non tumor-bearing mice without significant
increases in neutropenia (depletion of neutrophils, a type of white blood
cell) compared to chemotherapy alone.
"These findings clearly demonstrate the activity of our long acting
PEGPH20 enzyme candidate against HA-rich tumors in combination with
chemotherapy," said Gregory Frost, PhD, Halozyme's Vice President and Chief
Scientific Officer. "By targeting tumors that overproduce the HA matrix
component, PEGPH20 may selectively attack tumor interstitial fluid pressure
and combined with chemotherapy, reduce tumor burden for a significant
number of patients."
Halozyme is continuing its pharmacology, manufacturing and toxicology
studies as part of its PEGPH20 development program in oncology. The company
is making preparations for a pre-IND meeting with the FDA later this year
to seek advice with regard to the design of its first-in-human clinical
trial and plans to initiate studies in cancer patients with PEGPH20 during
the first half of 2009.
Study Details and Background
This study utilized three widely accepted animal cancer models:
xenograft PC3, xenograft Du145luc, and PC3-M-luc bone metastases. For the
HA-producing xenograft PC3 model, animals received an intramuscular
inoculation with PC3 prostate carcinoma cells in the hind leg in order to
generate tumors with high IFP. When tumor volume reached 400-500 mm(3), a
high tumor burden, animals were randomized to receive one of four possible
treatments: PEGPH20 alone, chemotherapy alone, chemotherapy plus PEGPH20,
or placebo. Two chemotherapeutic agents, docetaxel and liposomal
doxorubicin, were tested in this model. The non-HA-producing xenograft
Du145luc model was utilized in a similar manner with docetaxel. Finally, an
HA-producing PC3-M-luc disseminated bone metastasis model was used to test
PEGPH20 alone and in combination with docetaxel.
Xenograft PC3 results
-- Tumor volume growth suppressed significantly. Tumor volume growth
over time was significantly lower in the PEGPH20 plus docetaxel (p
Halozyme terapeutice Announces pozitive Cu Pegylated Enzyme În cancerul de prostatã modelele - Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme In Prostate Cancer Models - articole medicale engleza - startsanatate